1. Home
  2. BWB vs MNPR Comparison

BWB vs MNPR Comparison

Compare BWB & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bridgewater Bancshares Inc.

BWB

Bridgewater Bancshares Inc.

HOLD

Current Price

$20.71

Market Cap

562.1M

Sector

Finance

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$73.82

Market Cap

587.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BWB
MNPR
Founded
2005
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
562.1M
587.4M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
BWB
MNPR
Price
$20.71
$73.82
Analyst Decision
Strong Buy
Buy
Analyst Count
4
12
Target Price
$24.00
★ $129.92
AVG Volume (30 Days)
71.7K
★ 130.1K
Earning Date
10-20-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
44.66
★ 54.99
EPS
★ 1.03
N/A
Revenue
N/A
N/A
Revenue This Year
$21.45
N/A
Revenue Next Year
$11.22
N/A
P/E Ratio
$20.03
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.06
$50.07
52 Week High
$22.62
$124.82

Technical Indicators

Market Signals
Indicator
BWB
MNPR
Relative Strength Index (RSI) 48.31 33.31
Support Level $19.58 $51.32
Resistance Level $20.99 $76.13
Average True Range (ATR) 0.43 3.97
MACD 0.05 0.44
Stochastic Oscillator 52.73 28.32

Price Performance

Historical Comparison
BWB
MNPR

About BWB Bridgewater Bancshares Inc.

Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: